EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Exploratory proteomic and bioinformatics analysis unveils epitope pairing between IGHV3-64 and K-Ras for polyclonal drug conjugation in colorectal cancer

Raajesh Anand, Siva Kaliyamoorthy, Vinoth Boopathy, Jawahar Ramasamy, Ravikumar Sambandam

Exploration of Immunology · 07.05.2026 · 6

DOI: 10.37349/ei.2026.1003252 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Exploration of Immunology, online erschienen am 07.05.2026. Verfasst von Raajesh Anand und 4 weiteren Autor:innen. Die Arbeit nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

Colorectal cancer (CRC) remains the second leading cause of cancer-related mortality worldwide. While antibody-drug conjugates (ADCs) offer targeted therapeutic options, they are often limited by toxicity, immunogenicity, complex pharmacokinetics, and high production costs. Polyclonal antibodies—capable of recognizing multiple epitopes—present a promising, yet underexplored, alternative for targeted drug delivery. The stage-specific presence of secreted, stable immunoglobulins (IGs) in CRC and their potential utility in drug conjugation strategies remain largely uncharacterized.

Methods

This study utilized electrospray ionization nano-liquid chromatography tandem mass spectrometry (ESI-nanoLC-MS/MS) proteomic analysis on pre-treatment plasma samples across CRC stages to identify stage-specific IGs. Venn diagram comparisons refined IG candidates, while protein stability was assessed using ProtParam. Molecular docking simulations (via CB-Dock2), epitope mapping (via CABS-dock), and cell-penetrating peptide (CPP) prediction were integrated to explore epitope pairing between IGs and Kirsten rat sarcoma viral oncogene homolog (K-Ras) neoantigen, evaluating their potential for polyclonal drug conjugates (pPDCs).

Results

A total of 325 secreted IGs were initially identified, with 46 found to be stage-specific. Protein stability analysis shortlisted 5 IGs—3 for early-stage and 2 for advanced-stage CRC. Molecular docking revealed that IG heavy variable 3-64 (IGHV3-64) exhibited high-affinity binding with Irinotecan [binding free energy (ΔG) = −10.0 kcal/mol] and showed epitope-level pairing with K-Ras at residues 2–17 and 106–114. Additional CPP motif analysis supported the potential of IGHV3-64-derived peptides for intracellular delivery, reinforcing their promise in pPDC development.

Conclusions

IGHV3-64 emerges as a strong candidate biomarker for advanced-stage CRC, demonstrating consistent binding affinity to Irinotecan and epitope pairing with K-Ras. Its inherent CPP features further support its potential for targeted, intracellular delivery in pPDCs design. These findings highlight a novel direction in personalized cancer immunotherapy, warranting further in vitro and in vivo validation to confirm clinical utility.

Zitieren

APA

Anand, R., Kaliyamoorthy, S., Boopathy, V., Ramasamy, J., & Sambandam, R. (2026). Exploratory proteomic and bioinformatics analysis unveils epitope pairing between IGHV3-64 and K-Ras for polyclonal drug conjugation in colorectal cancer. Exploration of Immunology, 6. https://doi.org/10.37349/ei.2026.1003252

Vancouver

Anand R, Kaliyamoorthy S, Boopathy V, Ramasamy J, Sambandam R. Exploratory proteomic and bioinformatics analysis unveils epitope pairing between IGHV3-64 and K-Ras for polyclonal drug conjugation in colorectal cancer. Exploration of Immunology. 2026;6. doi:10.37349/ei.2026.1003252

BibTeX
@article{Anand2026,
  author = {Anand, Raajesh and Kaliyamoorthy, Siva and Boopathy, Vinoth and Ramasamy, Jawahar and Sambandam, Ravikumar},
  title = {Exploratory proteomic and bioinformatics analysis unveils epitope pairing between IGHV3-64 and K-Ras for polyclonal drug conjugation in colorectal cancer},
  journal = {Exploration of Immunology},
  year = {2026},
  volume = {6},
  doi = {10.37349/ei.2026.1003252}
}
Kostenlos starten →